The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Open accessAbstract
The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
The Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381
YAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628
A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer
Jiao, S., Wang, H., Shi, Z., Dong, A., Zhang, W., Song, X., He, F., Wang, Y., Zhang, Z., Wang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.010 · Cited by 602
Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
Antonescu, C. R., Le Loarer, F., Mosquera, J., Sboner, A., Zhang, L., Chen, C., Chen, H., Pathan, N., Krausz, T., Dickson, B. C., et al. (2013) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22073 · Cited by 597
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Liu, C.-Y., Zha, Z.-Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan, S. W., Lim, C. J., Hong, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152942 · Cited by 525
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.001 · Cited by 500
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Yu, F.-X., Luo, J., Mo, J.-S., Liu, G., Kim, Y. C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.017 · Cited by 463
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K.-L. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 431
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Lai, D., Ho, K. C., Hao, Y., & Yang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2711 · Cited by 416
Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration
Fan, F., He, Z., Kong, L.-L., Chen, Q., Yuan, Q., Zhang, S., Ye, J., Liu, H., Sun, X., Geng, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2304 · Cited by 382
Fan, R., Kim, N.-G., & Gumbiner, B. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216462110 · Cited by 336
Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer
Mori, M., Triboulet, R., Mohseni, M., Schlegelmilch, K., Shrestha, K., Camargo, F. D., & Gregory, R. I. (2014) · Cell · doi:10.1016/j.cell.2013.12.043 · Cited by 335
Touil, Y., Igoudjil, W., Corvaisier, M., Dessein, A.-F., Vandomme, J., Monté, D., Stechly, L., Skrypek, N., Langlois, C., Grard, G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1854 · Cited by 332
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
Janse van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 306
Nehme, N. T., Schmid, J. P., Debeurme, F., André-Schmutz, I., Lim, A., Nitschke, P., Rieux-Laucat, F., Lutz, P., Picard, C., Mahlaoui, N., et al. (2012) · Blood · doi:10.1182/blood-2011-09-378364 · Cited by 283
Noland, C. L., Gierke, S., Schnier, P. D., Murray, J., Sandoval, W. N., Sagolla, M., Dey, A., Hannoush, R. N., Fairbrother, W. J., & Cunningham, C. N. (2016) · Structure · doi:10.1016/j.str.2015.11.005 · Cited by 262
Self-citationYAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties
Liu, A. M., Poon, R. T. P., & Luk, J. M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.036 · Cited by 232
YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity
Ni, X., Tao, J., Barbi, J., Chen, Q., Park, B. V., Li, Z., Zhang, N., Lebid, A., Ramaswamy, A., Wei, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1124 · Cited by 231
Brodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J. W., Gragoudas, E., & Vavvas, D. G. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.04.011 · Cited by 220
YAP/TAZ as therapeutic targets in cancer
Zanconato, F., Battilana, G., Cordenonsi, M., & Piccolo, S. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.05.002 · Cited by 213
Pobbati, A. V., Han, X., Hung, A. W., Weiguang, S., Huda, N., Chen, G.-Y., Kang, C., Chia, C. S. B., Luo, X., Hong, W., et al. (2015) · Structure · doi:10.1016/j.str.2015.09.009 · Cited by 206
Saladi, S. V., Ross, K., Karaayvaz, M., Tata, P. R., Mou, H., Rajagopal, J., Ramaswamy, S., & Ellisen, L. W. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.001 · Cited by 197
Wang, S., Xie, F., Chu, F., Zhang, Z., Yang, B., Dai, T., Gao, L., Wang, L., Ling, L., Jia, J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3744 · Cited by 196
Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 196
Bum-Erdene, K., Zhou, D., Gonzalez-Gutierrez, G., Ghozayel, M. K., Si, Y., Xu, D., Shannon, H. E., Bailey, B. J., Corson, T. W., Pollok, K. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.010 · Cited by 193
Fang, L., Teng, H., Wang, Y., Liao, G., Weng, L., Li, Y., Wang, X., Jin, J., Jiao, C., Chen, L., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.002 · Cited by 184
Oku, Y., Nishiya, N., Shito, T., Yamamoto, R., Yamamoto, Y., Oyama, C., & Uehara, Y. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.06.007 · Cited by 179
Zhang, Z., Lin, Z., Zhou, Z., Shen, H. C., Yan, S. F., Mayweg, A. V., Xu, Z., Qin, N., Wong, J. C., Zhang, Z., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500160m · Cited by 174
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 172
Structural and Functional Similarity between the Vgll1-TEAD and the YAP-TEAD Complexes
Pobbati, A. V., Chan, S. W., Lee, I., Song, H., & Hong, W. (2012) · Structure · doi:10.1016/j.str.2012.04.004 · Cited by 169
miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis
Kang, W., Huang, T., Zhou, Y., Zhang, J., Lung, R. W. M., Tong, J. H. M., Chan, A. W. H., Zhang, B., Wong, C. C., Wu, F., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0134-0 · Cited by 162
Dhanasekaran, S. M., Balbin, O. A., Chen, G., Nadal, E., Sundaram, S. K., Pan, J., Veeneman, B. A., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 160
García-Rendueles, M. E. R., Ricarte‐Filho, J. C., Untch, B. R., Landa, I., Knauf, J. A., Voza, F. A., Smith, V. E., Ganly, I., Taylor, B. S., Persaud, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0330 · Cited by 151
Lee, J. E., Park, H. S., Lee, D., Yoo, G., Kim, T., Jeon, H., Yeo, M., Lee, C. S., Moon, J. Y., Jung, S. S., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.089 · Cited by 128
Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein
Tanas, M. R., Ma, S., Jadaan, F. O., Ng, C. K. Y., Weigelt, B., Reis-Filho, J. S., & Rubin, B. P. (2015) · Oncogene · doi:10.1038/onc.2015.148 · Cited by 121
Ren, A., Yan, G., You, B., & Sun, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6248 · Cited by 114
Non-Photoinduced Biological Properties of Verteporfin
Gibault, F., Corvaisier, M., Bailly, F., Huet, G., Melnyk, P., & Cotelle, P. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160316125048 · Cited by 112
Targeting Transcriptional Enhanced Associate Domains (TEADs)
Gibault, F., Sturbaut, M., Bailly, F., Melnyk, P., & Cotelle, P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00879 · Cited by 108
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 106
Zhao, Y., Khanal, P., Savage, P. B., She, Y., Cyr, T. D., & Yang, X. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2712 · Cited by 102
Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma
Huo, X., Zhang, Q., Liu, A. M., Tang, C., Gong, Y., Bian, J., Luk, J. M., Xu, Z., & Chen, J. (2012) · Oncology Reports · doi:10.3892/or.2012.2176 · Cited by 94
Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review
Crawford, J. J., Bronner, S. M., & Zbieg, J. R. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1549226 · Cited by 88
Self-citationGarcía‐Escudero, R., Segrelles, C., Dueñas, M., Pombo, M. T., Ballestín, C., Alonso, M., Nenclares, P., Álvarez‐Rodríguez, R., Aniceto, G. S., Ruiz-Alonso, A., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.02.014 · Cited by 79
Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ
Mesrouze, Y., Meyerhofer, M., Bokhovchuk, F. M., Fontana, P., Zimmermann, C., Martin, T., Delaunay, C., Izaac, A., Kallen, J. A., Schmelzle, T., et al. (2017) · Protein Science · doi:10.1002/pro.3312 · Cited by 73
Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73
Kawahara, M., Hori, T., Chonabayashi, K., Oka, T., Sudol, M., & Uchiyama, T. (2008) · Blood · doi:10.1182/blood-2007-09-111773 · Cited by 65
Mesrouze, Y., Bokhovchuk, F. M., Meyerhofer, M., Fontana, P., Zimmermann, C., Martin, T., Delaunay, C., Erdmann, D., Schmelzle, T., & Chêne, P. (2017) · eLife · doi:10.7554/elife.25068 · Cited by 60
Grieve, S., & Yang, X. (2009) · Gene · doi:10.1016/j.gene.2009.09.008 · Cited by 48
Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling
Zhao, Y., & Yang, X. (2015) · Oncotarget · doi:10.18632/oncotarget.4259 · Cited by 26
Cited by
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Self-citationThe Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Ju, J., Zhang, H., Lin, M., Yan, Z., An, L., Cao, Z., Geng, D., Yue, J., Tang, Y., Tian, L., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174587 · Cited by 338
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Self-citation
Metadata
- Authors
- Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 5
- Issue
- 5
- Pages
- 297-307
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2946065961
- Cited by
- 420
- References
- 63
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.